Elicio’s Novel TCR-T Cell Therapy Successfully Targets KRAS-Mutated Tumors

ONCOLIFE (pages 32-33): Elicio’s innovative approach involves coupling this therapy with AMP immunotherapy, which is strategically delivered to lymph nodes – the command centers of the immune system. This combination has shown remarkable success in not only eradicating established murine solid tumors that were resistant to TCR-T cell monotherapy but also in providing long-term protection against tumor recurrence.